+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Resistance to gentamicin, amikacin and ciprofloxacin among nosocomial isolates of klebsiella pneumoniae subspecie pneumoniae producing extended spectrum beta-lactamases



Resistance to gentamicin, amikacin and ciprofloxacin among nosocomial isolates of klebsiella pneumoniae subspecie pneumoniae producing extended spectrum beta-lactamases



Revista Medica de Chile 132(10): 1173-1178



Klebsiella pneumoniae is a pathogenic bacterium frequently isolated from nosocomial samples, specially the subspecie pneunonlae, with extensive antibiolic resistance profiles, including third generation cepbhalosporiis, aminoglycosides and quinolones. This is specially true for those strains producing extended spectrum beta lactamases (ESBL). To investigate the susceptibility to gentamicin, amikacin and ciprofloxacin and the presence of some aminogloycoside modifying enzyme (AMEs) among nosocomial strains of K pneumoniae subspecie pneumoniae producing ESBL. The antibiotic resistant patterns and the level of resistance (minimal inhibitory concentration, MIC) of 100 strains, isoklted from sel ,eal bospitals of dcifferent Chilean cities, were deterl,in,ed. Tbe presence of some aminoglycosides modifying enzyme (AMEs) was investigated by PCR. Sixty five percent of strains were resistant to gentamicin, 47% were resistant to amikacin, and 29% were resistant to ciprofloxacin. The most frequent AMEs genes detected were the aac(6')-Ib gene (6'N-Acetyltransferase type Ib enzyme) in 69% of strains, conferring resistance to amikacin, kanamycin, tobramycin, and nieoniycin, and the gene aac(3)-IIa (3-Acetyltransferase type 3-IIa enzyme), in 36% of strains, conferring resistance to gentamlicin. Among nosocomial strains of K pneumoniae subspecie pneumoniae isolaterd from Chilean hospitals, there is an association between the production of ESBL and the resistance to others antimicrobial agents, especially aminoglycosides. Nevertheless, 71% of isolates are susceptible to ciprofloxacin.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050191263

Download citation: RISBibTeXText

PMID: 15631204


Related references

In vitro bactericidal activity of imipenem in combination with amikacin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Pharmacotherapy 20(10): 1249, 2000

In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase. ChemoTherapy 43(4): 245-253, 1997

In vitro Time-Kill Curves of Cefepime and Cef pirome Combined with Amikacin, Gentamicin or Ciprofloxacin against Klebsiella pneumoniae Producing Extended-Spectrum Beta-Lactamase. Chemotherapy 43(4): 245-253, 1997

Distribution of SHV genotypes and resistance analysis of extended-spectrum beta-lactamases-producing klebsiella pneumoniae and escherichia coli isolates in Hefei. Zhongguo Yaolixue Tongbao 23(6): 812-815, 2007

Molecular epidemiology of nosocomial infection by extended-spectrum beta-lactamases-producing Klebsiella pneumoniae. Biomedica 24(3): 252-261, 2004

Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. Antimicrobial Agents and ChemoTherapy 53(1): 104-111, 2009

Role of contaminated aspiration tubes in nosocomial outbreak of Klebsiella pneumoniae producing SHV-2 and CTX-M-15 extended-spectrum beta-lactamases. Journal of Hospital Infection 72(1): 23-29, 2009

First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea. Antimicrobial Agents and ChemoTherapy 49(11): 4809-4810, 2005

Observation on integron carriage among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Indian Journal of Medical Microbiology 28(3): 207-210, 2010

Survey on antibiotic-resistance of extended-spectrum beta-lactamases producing Klebsiella pneumoniae. Zhongguo Kangshengsu Zazhi 29(4): 235-237, 254, 2004

Long-term study of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases. Journal of the Medical Association of Thailand 92(Suppl. 4): S53-S58, 2009

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrobial Agents and ChemoTherapy 55(5): 2434-2437, 2011

The rate of isolation of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and resistance to antibiotics. Medicina 42(4): 288-293, 2006

Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrobial Agents and ChemoTherapy 48(9): 3477-3482, 2004

Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and deficient or not in porins. Journal of Antimicrobial ChemoTherapy 46(5): 858-859, 2000